CFTR and cystic fibrosis: Most CF patients are now on revolutionary CFTR potentiator and/or corrector therapies and these are likely to exert impacts on vitamin E pharmacokinetic via potential effects on bile and pancreatic secretions, enterocyte functions and modulations of the intensity of RT inflammatory processes [78,79,80,81,82,83,84,85].